Genetic background alters the severity and onset of neuromuscular disease caused by the loss of ubiquitin-specific protease 14 (Usp14)

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Marshall, Andrea G ^a   Watson, Jennifer A ^a   Hallengren, Jada J ^a   Walters, Brandon J ^a,b   Dobrunz, Lynn E ^a   Francillon, Ludwig ^a   Wilson, Julie A ^a   Phillips, Scott E ^a   Wilson, Scott M ^a  

^a University of Alabama at Birmingham   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; MESSENGER RNA; UBIQUITIN; UBIQUITIN SPECIFIC PROTEASE 14; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE COURSE; DISEASE SEVERITY; ENZYME DEFICIENCY; FACILITATION; GENE; GENE LOSS; GENE MUTATION; GENETIC TRAIT; HIPPOCAMPUS; LETHALITY; MOUSE; MUTANT; NERVE ENDING; NEUROAXONAL DYSTROPHY; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NMF375 GENE; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PERINATAL PERIOD; PROTEIN DEPLETION; PROTEIN STABILITY; PURKINJE CELL; RNA SPLICING; USP14 GENE;

ALTERNATIVE SPLICING; ANIMALS; AXONS; BASE SEQUENCE; CHROMOSOME MAPPING; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HIPPOCAMPUS; HOMEOSTASIS; HUMANS; MICE; MOTOR ENDPLATE; MUSCLE FIBERS, SKELETAL; MUTATION; NEUROMUSCULAR DISEASES; NEUROMUSCULAR JUNCTION; NEURONAL PLASTICITY; PHENOTYPE; PROTEIN SUBUNITS; PURKINJE CELLS; RECEPTORS, CHOLINERGIC; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYNAPSES; UBIQUITIN; UBIQUITIN THIOLESTERASE;

EID: 84892631732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084042     Document Type: Article

References (42)

1. Kearney JA (2011) Genetic modifiers of neurological disease. Curr Opin Genet Dev 21: 349-353. doi:10.1016/j.gde.2010.12.007. PubMed: 21251811.
2. Gillingwater TH, Wishart TM (2013) Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease. Neuropathology and Applied Neurobiology: n/a-n/a.
3. Huang Q, Figueiredo-Pereira ME (2010) Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 15: 1292-1311. doi:10.1007/s10495-010-0466-z. PubMed: 20131003.
4. Paul S (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 30: 1172-1184. doi:10.1002/bies.20852. PubMed: 18937370.
5. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM et al. (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: An initial assessment. J Alzheimers Dis 10: 391-397. PubMed: 17183150.
6. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM et al. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, α-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532. doi:10.1046/j.1471-4159. 2002.01103.x. PubMed: 12354300.
7. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M et al. (2004) Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases. J Biol Chem 279: 13256-13264. PubMed: 14722078.
8. Leroy E, Boyer R, Auburger G, Leube B, Ulm G et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452. doi:10.1038/26652. PubMed: 9774100.
9. Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51: 105-111. doi:10.1016/j.neuint. 2007.05.007. PubMed: 17586089.
10. Deng H-X, Chen W, Hong S-T, Boycott KM, Gorrie GH et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477: 211-215. doi:10.1038/nature10353. PubMed: 21857683.
11. Ramser J, Ahearn ME, Lenski C, Yariz KO, Hellebrand H et al. (2008) Rare Missense and Synonymous Variants in UBE1 Are Associated with X-Linked Infantile Spinal Muscular Atrophy. Am J Hum Genet 82: 188-193. doi:10.1016/j.ajhg.2007.09. 009. PubMed: 18179898.
12. Yi JJ, Ehlers MD (2007) Emerging roles for ubiquitin and protein degradation in neuronal function. Pharmacol Rev 59: 14-39. doi:10.1124/pr.59.1. 4. PubMed: 17329546.
13. Reyes-Turcu FE, Ventii KH, Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78: 363-397. doi:10.1146/annurev.biochem.78.082307.091526. PubMed: 19489724.
14. Wilson SM, Bhattacharyya B, Rachel RA, Coppola V, Tessarollo L et al. (2002) Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 32: 420-425. doi:10.1038/ng1006. PubMed: 12368914.
15. Bhattacharyya BJ, Wilson SM, Jung H, Miller RJ (2012) Altered neurotransmitter release machinery in mice deficient for the deubiquitinating enzyme Usp14. Am J Physiol Cell Physiol 302: C698-C708. PubMed: 22075695.
16. Chen PC, Bhattacharyya BJ, Hanna J, Minkel H, Wilson JA et al. (2011) Ubiquitin homeostasis is critical for synaptic development and function. J Neurosci 31: 17505-17513. doi:10.1523/JNEUROSCI.2922-11.2011. PubMed: 22131412.
17. Chen PC, Qin LN, Li XM, Walters BJ, Wilson JA et al. (2009) The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J Neurosci 29: 10909-10919. doi:10.1523/JNEUROSCI.2635-09.2009. PubMed: 19726649.
18. Anderson C, Crimmins S, Wilson JA, Korbel GA, Ploegh HL et al. (2005) Loss of Usp14 results in reduced levels of ubiquitin in ataxia mice. J Neurochem 95: 724-731. doi:10.1111/j.1471-4159.2005.03409.x. PubMed: 16190881.
19. Crimmins S, Jin Y, Wheeler C, Huffman AK, Chapman C et al. (2006) Transgenic rescue of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14. J Neurosci 26: 11423-11431. doi:10.1523/ JNEUROSCI.3600-06.2006. PubMed: 17079671.
20. Aljakna A, Choi S, Savage H, Hageman Blair R, Gu T et al. (2012) Pla2g12b and Hpn Are Genes Identified by Mouse ENU Mutagenesis That Affect HDL Cholesterol. PLOS ONE 7: e43139. doi:10.1371/journal.pone.0043139. PubMed: 22912808.
21. Chen B, Li K, Zhang F, Zhai G, Gong W et al. (2011) An ENU-Induced Mutation of Nrg1 Causes Dilated Pupils and a Reduction in Muscarinic Receptors in the Sphincter Pupillae. PLOS ONE 6: e25176. doi:10.1371/journal.pone.0025176. PubMed: 21949880.
22. Gupta VA, Kawahara G, Myers JA, Chen AT, Hall TE et al. (2012) A Splice Site Mutation in Laminin Results in a Severe Muscular Dystrophy and Growth Abnormalities in Zebrafish. PLOS ONE 7: e43794. doi:10.1371/journal.pone. 0043794. PubMed: 22952766.
23. Wu J-Y, Kao H-J, Li S-C, Stevens R, Hillman S et al. (2004) ENU mutagenesis identifies mice with mitochondrial branched-chain aminotransferase deficiency resembling human maple syrup urine disease. J Clin Invest 113: 434-440. doi:10.1172/JCI200419574. PubMed: 14755340.
24. Leggett DS, Hanna J, Borodovsky A, Crosas B, Schmidt M et al. (2002) Multiple Associated Proteins Regulate Proteasome Structure and Function. Mol Cell 10: 495-507. doi:10.1016/S1097-2765(02)00638-X. PubMed: 12408819.
25. Ryu K-Y, Maehr R, Gilchrist CA, Long MA, Bouley DM et al. (2007) The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance. EMBO J 26: 2693-2706. doi:10.1038/sj.emboj.7601722. PubMed: 17491588.
26. Duclert A, Changeux JP (1995) Acetylcholine receptor gene expression at the developing neuromuscular junction. Physiol Rev 75: 339-368. PubMed: 7724666.
27. Plomp JJ, Molenaar PC (1996) Involvement of protein kinases in the upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats. J Physiol 493: 175-186. PubMed: 8735703.
28. Jaweed MM, Herbison GJ, Ditunno JF (1975) Denervation and reinnervation of fast and slow muscles. A histochemical study in rats. Journal of Histochemistry and Cytochemistry 23: 808-827.
29. D'Amato CJ, Hicks SP (1965) Neuropathologic alterations in the ataxia (paralytic) mouse. Arch Pathol 80: 604-612. PubMed: 5855800.
30. Camu W, Khoris J, Moulard B, Salachas F, Briolotti V et al. (1999) Genetics of familial ALS and consequences for diagnosis. French ALS Research Group. J Neurol Sci 165: S21-S26. doi:10.1016/S0022-510X(99)00022-2. PubMed: 10448977.
31. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ et al. (2005) Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 236: 1-7. doi:10.1016/j.jns.2005.02.006. PubMed: 16024047.
32. Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H et al. (2003) Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 114: 11-21. doi:10.1007/s00439-003-1025-2. PubMed: 14520560.
33. Hanna J, Hathaway NA, Tone Y, Crosas B, Elsasser S et al. (2006) Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 127: 99-111. doi:10.1016/j.cell.2006.07.038. PubMed: 17018280.
34. Lee BH, Lee MJ, Park S, Oh DC, Elsasser S et al. (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467: 179-184. doi:10.1038/nature09299. PubMed: 20829789.
35. Jin YN, Chen PC, Watson JA, Walters BJ, Phillips SE et al. (2012) Usp14 deficiency increases tau phosphorylation without altering tau degradation or causing tau-dependent deficits. PLOS ONE 7: 29. PubMed: 23144711.
36. Walters BJ, Campbell SL, Chen PC, Taylor AP, Schroeder DG et al. (2008) Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity. Mol Cell Neurosci 39: 539-548. doi:10.1016/j.mcn.2008.07.028. PubMed: 18771733.
37. Crimmins S, Sutovsky M, Chen PC, Huffman AK, Wheeler C et al. (2009) Transgenic rescue of ataxia mice reveals a male-specific sterlity defect. Dev Biol 325: 33-42. doi:10.1016/j.ydbio.2008.09.021. PubMed: 18926813.
38. The Gene Expression Nervous System Atlas (GENSAT) Project, NINDS Contracts N01NS02331 & HHSN271200723701C to The Rockefeller University (New York, NY)."
39. Lappe-Siefke C, Loebrich S, Hevers W, Waidmann OB, Schweizer M, et et al. (2009). The ataxia (axJ) mutation causes abnormal GABAA receptor turnover in mice. PLoS Genet 5(9):e1000631
40. Tai HC, Besche H, Goldberg AL, Schuman EM (2010) Characterization of the Brain 26S Proteasome and its Interacting. Proteins - Frontiers in Neuroscience 3: 1-19.
41. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12: 1945-1958. doi:10.1093/hmg/ddg211. PubMed: 12913066.
42. Chen F, Sugiura Y, Myers KG, Liu Y, Lin W (2010) Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. Proc of the Natl Acad of Sciences of the USA 107: 1636-1641. doi:10.1073/pnas.0911516107. PubMed: 20080621.